Joe - New Portfolio

Shmozak

Joe
Individual Investor
Ranked #424,603 out of 764,630 TipRanks' Investors
Success Rate
44%
240 out of 544
profitable transactions
Average Return
-1.98%
Average return
per transaction
Share this portfolio:

Portfolio Gain

1-Month Return▲ 7.76%
6-Month Return▲ 37.20%
12-Month Return▲ 22.35%
YTD Return▲ 13.37%
Total Return▼ 38.44%

Best Trade

Opened at
Closed at-
Gain▲ 318.39%

Bio

My Best stock ideas. I trade often, and hold everything that I have in this portfolio.

Performance

43.78%0-43.78%
▲ 5.05%
▲ 3.27%
▼ 1.43%
Mar 2024
▼ 12.40%
▼ 4.03%
▼ 11.08%
Apr 2024
▲ 11.46%
▲ 5.06%
▲ 0.30%
May 2024
▼ 2.25%
▲ 3.53%
▲ 43.78%
Jun 2024
▲ 25.72%
▲ 1.21%
▼ 6.59%
Jul 2024
▼ 4.21%
▲ 2.34%
▼ 3.10%
Aug 2024
▲ 7.82%
▲ 2.10%
▲ 2.08%
Sep 2024
▲ 6.02%
▼ 0.89%
▲ 6.74%
Oct 2024
TipRanks AverageS&P 500Investor Portfolio
▲ 5.05%▲ 3.27%▼ 1.43%
▼ 12.40%▼ 4.03%▼ 11.08%
▲ 11.46%▲ 5.06%▲ 0.30%
▼ 2.25%▲ 3.53%▲ 43.78%
▲ 25.72%▲ 1.21%▼ 6.59%
▼ 4.21%▲ 2.34%▼ 3.10%
▲ 7.82%▲ 2.10%▲ 2.08%
▲ 6.02%▼ 0.89%▲ 6.74%

Recent Activity

Company Name
% of Portfolio
Return
No. of Transactions
Last Transaction
Date
ZyVersa Therapeutics
25%
▼ 28.18%
3
Open
Jan 17, 2024
Minim, Inc.
▼ 37.02%
2
Close
Jan 17, 2024
Spectaire Holdings
▼ 3.43%
2
Close
Jan 17, 2024
Jeffs' Brands Ltd.
▼ 10.16%
2
Close
Jan 12, 2024
Axonics Modulation Technologies
▼ 0.92%
2
Close
Jan 12, 2024
Juniper Networks
▲ 1.90%
2
Close
Jan 12, 2024
Pricesmart
▲ 0.63%
2
Close
Jan 12, 2024
Flexsteel
25%
▲ 144.77%
1
Open
Jan 12, 2024
Sentage Holdings
▼ 17.91%
4
Close
Jan 11, 2024
Harpoon Therapeutics
▲ 0.40%
2
Close
Jan 11, 2024
Ambrx Biopharma
▲ 2.26%
2
Close
Jan 11, 2024
Ainos
▼ 13.55%
4
Close
Jan 10, 2024
Aclarion, Inc.
▼ 18.92%
6
Close
Jan 10, 2024
Dyne Therapeutics
▲ 22.07%
2
Close
Jan 08, 2024
Omega Therapeutics
▼ 18.16%
2
Close
Jan 08, 2024
NexImmune
▼ 1.01%
4
Close
Jan 05, 2024
Entero Therapeutics
▲ 0.42%
6
Close
Jan 05, 2024
Dermata Therapeutics
25%
▼ 53.88%
3
Open
Jan 05, 2024
Voyager Therapeutics
▼ 1.67%
2
Close
Jan 05, 2024
Cue Health
▼ 10.09%
2
Close
Jan 05, 2024